ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,770.20
0.55%
US Tech 100
19,636.04
0.55%
다우존스 지수
42,801.72
0.52%
Bitcoin
86,026.46
-0.15%
Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ

  6. ImmunityBio Inc (IBRX) 시세

ImmunityBio Inc

ImmunityBio Inc (IBRX)

NASDAQ
3.00
0.01
(0.33%)
마감 09 3월 6:00AM
15분 지연
3.04
0.04
(1.33%)
시간외 거래: 9:56AM
15분 지연

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

프리미엄

주요 통계 및 세부정보

가격
3.04
매수가
2.97
매도가
3.03
거래량
4,017,773
2.9111 일간 변동폭 3.065
2.28 52주 범위 10.53
market_cap
2.118B
전일 종가
2.99
개장가
2.955
최근 거래 시간
70
@
3.03
마지막 거래 시간
재정 규모
US$ 12,050,134
VWAP
2.9992
평균 볼륨(3m)
6,359,357
발행 주식
696,831,296
배당수익률
-
주가수익률
-38.82
주당순이익(EPS)
-0.84
매출
622k
순이익
-583.2M

ImmunityBio Inc 정보

ImmunityBio Inc is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate (natural killer cell and macrophage) and adaptive (T cel... ImmunityBio Inc is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems to create long-term immunological memory. 더 보기

섹터
Biological Pds,ex Diagnstics
산업
Biological Pds,ex Diagnstics
웹사이트
www.immunitybio.com
본부
Wilmington, Delaware, USA
설립됨
-
ImmunityBio Inc is listed in the Biological Pds,ex Diagnstics sector of the 나스닥 with ticker IBRX. The last closing price for ImmunityBio was US$2.99. Over the last year, ImmunityBio shares have traded in a share price range of US$ 2.28 to US$ 10.53.

ImmunityBio currently has 696,831,296 shares in issue. The market capitalisation of ImmunityBio is US$2.08 billion. ImmunityBio has a price to earnings ratio (PE ratio) of -38.82.

IBRX 최신 뉴스

추가 뉴스

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Edgar (US Regulatory)
03 3월 2025
IBRX (0.33%)

Form 8-K - Current report
Edgar (US Regulatory)
03 3월 2025
IBRX (0.33%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
26 2월 2025
IBRX (0.33%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
26 2월 2025
IBRX (0.33%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
26 2월 2025
IBRX (0.33%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
13 2월 2025
IBRX (0.33%)
기간변동변동 %시가고가저가평균 일일 거래량VWAP
1-0.07-2.250803858523.113.512.777870243.07573406CS
4-0.35-10.32448377583.394.272.763111583.32323227CS
120.02370.7857308623153.01634.272.2863593573.04775469CS
26-0.41-11.8840579713.457.482.2858230833.88499633CS
52-2.01-39.8019801985.0510.532.2854315215.11966347CS
156-2.98-49.50166112966.0210.531.2139046804.2171338CS
260-33.51-91.68262653936.5540.8341.2132512224.95184634CS

IBRX - Frequently Asked Questions (FAQ)

What is the current ImmunityBio share price?
The current share price of ImmunityBio is US$ 3.04
How many ImmunityBio shares are in issue?
ImmunityBio has 696,831,296 shares in issue
What is the market cap of ImmunityBio?
The market capitalisation of ImmunityBio is USD 2.08B
What is the 1 year trading range for ImmunityBio share price?
ImmunityBio has traded in the range of US$ 2.28 to US$ 10.53 during the past year
What is the PE ratio of ImmunityBio?
The price to earnings ratio of ImmunityBio is -38.82
What is the cash to sales ratio of ImmunityBio?
The cash to sales ratio of ImmunityBio is 36.1k
What is the reporting currency for ImmunityBio?
ImmunityBio reports financial results in USD
What is the latest annual turnover for ImmunityBio?
The latest annual turnover of ImmunityBio is USD 622k
What is the latest annual profit for ImmunityBio?
The latest annual profit of ImmunityBio is USD -583.2M
What is the registered address of ImmunityBio?
The registered address for ImmunityBio is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the ImmunityBio website address?
The website address for ImmunityBio is www.immunitybio.com
Which industry sector does ImmunityBio operate in?
ImmunityBio operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
ABLVAble View Global Inc
US$ 1.73
(137.18%)
5.14M
SUNESUNation Energy Inc
US$ 0.402999
(127.55%)
482.05M
BTOGBit Origin Ltd
US$ 0.6117
(118.46%)
622.67M
DWTXDogwood Therapeutics Inc
US$ 6.63
(49.66%)
25.92M
KZIAKazia Therapeutics Ltd
US$ 1.1899
(40.80%)
4.5M
ALBTAvalon GloboCare Corporation
US$ 6.96
(-36.15%)
577.55k
SCNXScienture Holdings Inc
US$ 1.55
(-35.68%)
1.59M
ACXPAcurx Pharmaceuticals Inc
US$ 0.4572
(-29.88%)
1.18M
RETOReTo Eco Solutions Inc
US$ 5.42
(-27.73%)
108.27k
OCTOEightco Holdings Inc
US$ 1.08
(-27.03%)
336.99k
BTOGBit Origin Ltd
US$ 0.6117
(118.46%)
622.67M
SUNESUNation Energy Inc
US$ 0.402999
(127.55%)
482.05M
NVDANVIDIA Corporation
US$ 112.69
(1.92%)
341.94M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 10.675
(-0.70%)
143.04M
ICONIcon Energy Corporation
US$ 0.169898
(17.17%)
142.23M

IBRX Discussion

게시물 보기
glenn1919 glenn1919 4 일 전
IBRX.....................................https://stockcharts.com/h-sc/ui?s=IBRX&p=W&b=5&g=0&id=p86431144783
👍️0
Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 6 일 전
please interpret
👍️0
glenn1919 glenn1919 1 주 전
IBRX.............https://stockcharts.com/h-sc/ui?s=IBRX&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 2 주 전
IBRX.......................................https://stockcharts.com/h-sc/ui?s=IBRX&p=W&b=5&g=0&id=p86431144783
👍️0
Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 2 주 전
great news today. so much potential for this company
👍️0
TrendTrade2016 TrendTrade2016 2 주 전
IBRX BIO BEST OF THE DAY
👍️ 1 😁 1
jondoeuk jondoeuk 3 주 전
Five cases in patients all with metastatic pancreatic cancer https://pmc.ncbi.nlm.nih.gov/articles/PMC11813753/
👍️0
westjtter westjtter 4 주 전
I agree....looks like she is getting ready to make a move higher🤞....would be nice to make a strong move over $3.50 and then consolidate here before a move back over $4! It is all about funding IMO!
👍️0
Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 1 월 전
Another nice finish. Building strength!
👍️0
Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 1 월 전
did very well today and this week despite MMs attempt to hold it down
future looks bright 😎
👍️0
westjtter westjtter 1 월 전
yup....I think PSS has a lot more in the hamper....2025 and 2026 are going to be very big for this stock! IMO
👍️0
Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 2 월 전
Things sure change fast with this stock.
FDA posting is BIG
👍️0
tw0122 tw0122 2 월 전
Liking it zone up next  $3.23 to $3.70 some being hit now. 
$3.22 +'5% 
👍️ 1
westjtter westjtter 2 월 전
Well that was a pretty great day up 27%....is this the beginning of the runnup or just a short term pump? Regardless, whether the share price does back off or not, still believe longer term...even just year end, this is going to be a lot higher.

And of course, if Anktiva worldwide approvals continue, revenue starts ramping up, and trials continue to throw off strong data.....well then the share price does have a long way to run....we will see!
👍️ 1
glenn1919 glenn1919 2 월 전
IBRX....................https://stockcharts.com/h-sc/ui?s=IBRX&p=W&b=5&g=0&id=p86431144783
👍️0
westjtter westjtter 2 월 전
I agree...typically the underwriters support the stock for at least a short period of time(1 to 2 months anyway) so that the offering looks OK to their customers....this one is very strange as the stock has just kept falling...which really does not make a lot of sense if you look at where it was trading before the offering and the price target from their analysts???

I am considering this an anomaly, and have continued to buy and build a position......am I missing something???
👍️0
Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 2 월 전
People who bought the december offering at $3 a share sure are tasting some pain. Surprise the underwriters arent supporting the stock better.
👍️0
Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 2 월 전
ImmunityBio has granted the underwriters a 30-day option to purchase up to an additional 5,000,000 shares of its common stock at the public offering price
I wonder if the underwriters exercised this option or not. $3 share price doesnt look to great a deal at the moment.
👍️0
westjtter westjtter 2 월 전
Yes, I believe that management has a plan and this is the first of a slew of positive news coming in 2025....and the bet is that this may be their final equity raise....or at least their final equity raise in the lower single digits....next one(if required) could be in the teens?

I think buying under $3 is as close as you can get to a slam dunk....at the very least, you will see this stock jump up to the mid $3's which will allow a quick profit on a trade....I happen to think that while the share price may be somewhat volatile, we are going a lot higher in 2025.....As for the $30 price target by one of the analysts covering the stock....while that would obviously be a huge upside surprise....I am thinking that upper single digits in 2025 would be a more reasonable guesstimate of where this stock price may be going.

So you can buy for the trade, or you can buy for a longer hold and a decent shot at a huge upside on the share price...IMO of course!!!
👍️ 1
Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 2 월 전
IBRX today announced the unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code assigned by the Centers for Medicare & Medicaid Services (CMS) for ANKTIVA® (nogapendekin alfa inbakicept-pmln) became effective January 1, 2025. The U.S. Food and Drug Administration (FDA) approved ANKTIVA with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors.

Healthcare providers may now use the permanent J-code, J9028 (Injection, nogapendekin alfa inbakicept-pmln, for intravesical use, 1 microgram), when submitting claims for ANKTIVA. J-codes are unique identifiers used by U.S. government and commercial payers, as well as physicians and their office staff, to streamline the billing and reimbursement process for intravesically administered therapies and certain other treatments.

More evidence of a revenue ramp-up
👍️0
westjtter westjtter 2 월 전
Here is how I see it…anything under $3 is a real bargain……I see the stock going up at least 20% in the coming months…so you could buy this thing just for a trade ! However i believe it is going a lot higher…the fact that PSS only raised $100 mil, indicates that management believes there is a big jump in revenue coming in 2025, and there will be plenty of news to support the stock price! We will see!
👍️ 2 😁 1
Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 2 월 전
Should climb over $3 as offering closed at $3
Bankers begin support and tax loss selling ends today
January effect should be good
👍️ 1
Monksdream Monksdream 3 월 전
IBRX under $3
👍️0
westjtter westjtter 3 월 전
Anyone know if the $100 million in stock offering(33 mil shares) is now complete? This was originally to close around Dec 12th....also there was an option for an additional 5 million shares to the underwriters for 30 more days after closing.

Just curious as to who were the buyers of this stock? I would hope and think once this offering closes the share price should slowly start to head higher again.
👍️0
Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 3 월 전
Sub $2.50 next week?
Year-end selling killing this one...or is it something else?
👍️0
jondoeuk jondoeuk 3 월 전
This will be interesting, but we know that cancer cells are able to develop multiple mechanisms that enable the evasion of NKs. These mechanisms are likely the reason why NK based therapies show only limited success in clinic trials. Here is just one mechanism (that was recently found) https://www.cell.com/cell/abstract/S0092-8674(24)00355-6

https://x.com/DrPatSoonShiong/status/1861433583186932141
👍️0
jondoeuk jondoeuk 3 월 전
A new paper on anti-HER2 CAR-NKs (+/- anti-PD-1) https://academic.oup.com/neuro-oncology/article/26/Supplement_8/viii85/7890050
👍️0
Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 4 월 전
what do you think is the biggest factor for the recent rise?
👍️0
glenn1919 glenn1919 4 월 전
IBRX........................https://stockcharts.com/h-sc/ui?s=IBRX&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 4 월 전
IBRX ROCKET SHIP
👍️0
TrendTrade2016 TrendTrade2016 4 월 전
IBRX PUSH PUSH PUSH
👍️0
glenn1919 glenn1919 4 월 전
IBRX...................................https://stockcharts.com/h-sc/ui?s=IBRX&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 4 월 전
IBRX BIO BEAST
👍️0
tw0122 tw0122 4 월 전
Not bad $5.13 + 28%
👍️0
jondoeuk jondoeuk 5 월 전
A case report. From it: ''Here, we report the compassionate use treatment of this combination in a patient with recurrent, metastatic pancreatic cancer (mPC) after 3 lines of therapy. Under the initial single-patient Investigational New Drug (spIND) protocol, the patient received N-803, PD-L1 t-haNK cells, and the albumin doxorubicin conjugate aldoxorubicin for ~27 months. The patient's disease became stable on this regimen, and a transient complete response was observed by ~14 months of therapy. Due to progression, a second spIND protocol was designed whereby the patient received E-EDV-D682 plus EDV-GC for more than 24 months, which resulted in stable disease and the patient's continued survival at the time this report was written.'' https://academic.oup.com/oncolo/advance-article/doi/10.1093/oncolo/oyae267/7814737
👍️ 2
aBeezlee aBeezlee 5 월 전
$2 would be great. We'll see.
👍️0
Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 5 월 전
Wait until it hits $2.50

Hold!
👍️0
axelvento axelvento 6 월 전
bouncer$ ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer

https://immunitybio.com/immunitybio-presents-positive-long-term-overall-survival-data-in-non-small-cell-lung-cancer-patients-and-announces-registrational-intent-phase-3-trials-with-anktiva-and-checkpoint-immunotherapy/
👍️0
Monksdream Monksdream 6 월 전
IBRX under $4
👍️0
Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 7 월 전
Down and down, is approval for other cancer expected in June dead?
👍️0
Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 7 월 전
Why did IBRX tank so badly in mid August?
👍️0
Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 7 월 전
IBRX at $4

Wow. Where is the pancreatic cancer approval expected in June?

👍️0
Monksdream Monksdream 7 월 전
IBRX under $6
👍️0
Monksdream Monksdream 8 월 전
IBRX under $10
👍️0
jgrabar jgrabar 8 월 전
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of ImmunityBio, Inc. (IBRX)
See https://grabarlaw.com/the-latest/immunitybio-shareholder-investigation/
👍️0
tw0122 tw0122 9 월 전
09:45 AM EDT, 06/20/2024 (MT Newswires) -- ImmunityBio (IBRX) said Thursday that it has launched Anktiva, its immunotherapy to treat Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer, with multiple patients across the US receiving the initial commercial doses.

The US Food and Drug Administration approved Anktiva in April to treat patients with BCG-unresponsive non-muscle invasive bladder cancer with or without papillary tumors, according to ImmunityBio.
👍️0
Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 9 월 전
Any thoughts on how much revenue FDA approval will bring?
👍️0
wrk_SATX wrk_SATX 10 월 전
Still +54M shares short and time is ticking. 80% inside ownership with a small float.
👍️0
saigai saigai 10 월 전
up and down.. no problem.. ima staying put
👍️0
saigai saigai 10 월 전
we know there is a very large short position here.. i think that since the earnings post yesterday and the reaction to it that there is now very little reason to stay short,,lets see that spike
👍️0

최근 히스토리

NASDAQ
IBRX
ImmunityBio
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유

광고 제거

광고 없는 경험을 위해 가입하세요

광고 없음

지금 사용해 보세요

광고 유지